Cytomark  >  Resources  >  Bibliography


Bone Marrow Stabilisation


The utilisation of modern transport and telecommunications platforms to assist in the remote provision of paediatric cancer diagnostics in Tanzania

Sample Type: Bone marrow

Analysis Method: Flow Cytometry


M. Mcdermott, K. O'Hare, P. Scanlon, D. Grehan, S. Rooney, R. Laiti, J. Kaijage, S. Jumanne, M. O'Sullivan


Pediatric Blood and Cancer, 63: Supplement 3 (S71)

Conference Abstract: Interim diagnostic services were provided by OLCHC in Dublin for paediatric cancer screening in Tanzania utilising DHL to transport fixed bone marrow samples and communicating the results via the WhatsApp communication platform in an average of 2.9 days. The bone marrow samples were fixed with TransFix to maintain integrity during transportation.


KEY PAPER: The impact of stem cells on electron fluxes, proton translation, and ATP synthesis in kidney mitochondria after ischemia/reperfusion

Sample Type: Bone marrow-derived stem cells

Analysis Method: Flow Cytometry


Beiral HJ1, Rodrigues-Ferreira C, Fernandes AM, Gonsalez SR, Mortari NC, Takiya CM, Sorenson MM, Figueiredo-Freitas C, Galina A, Vieyra A.


Cell Transplant. 2014 Feb;23(2):207-20

This study aims to show the administration of bone marrow-derived stem cells (BMSCs) can aid recovery of mitochondrial respiration following ischemia/reperfusion (I/R) injuries. The BMSCs were used immediately following isolation from the extracted bone marrow and some were retained for characterisation. 3x106 of the BMSCs were resuspended in PBS and stabilised using 1 part TransFix to 5 parts cell suspension for subsequent immunophenotyping, allowing the researchers to complete other time sensitive aspects of the study.


KEY PAPER: Immunophenotypic Characterization of Bone Marrow Mast Cells in Mastocytosis and Other Mast Cell Disorders

Sample Type: Bone marrow (mast cells)

Analysis Method: Flow Cytometry


L. Sánchez-Munoz, C, Teodósio, J.M. Morgado and L. Escribano


Recent Advances in Cytometry, Part B - Methods in Cell Biology (Book Series), Vol. 103. P333-359, Book published by Academic Press June 2011

Mastocytosis is a term used to designate a heterogeneous group of disorders characterized by an abnormal proliferation and accumulation of mast cells (MCs) in one or multiple tissues including skin, bone marrow (BM), liver, spleen, and lymph nodes, among others. Recent advances in our understanding of mast cell biology and disease resulted in the identification of important differences in the expression of mast cell surface antigens between normal and neoplastic mast cells. Most notably, detection of aberrant expression of CD25 and CD2 on the surface of neoplastic mast cells but not on their normal counterparts lead to the inclusion of this immunophenotypic abnormality in the World Health Organization diagnostic criteria for systemic mastocytosis. Aberrant mast cell surface marker expression can be detected in the bone marrow aspirate by flow cytometry, even in patients lacking histopathologically detectable aggregates of mast cells in bone marrow biopsy sections. These aberrant immunophenotypic features are of great relevance for the assessment of tissue involvement in mastocytosis with consequences in the diagnosis, classification, and follow-up of the disease and in its differential diagnosis with other entities. In this chapter, we provide the reader with information for the objective and reproducible identification of pathologic MCs by using quantitative multiparametric flow cytometry, for their phenotypic characterization, and the criteria currently used for correct interpretation of the immunophenotypic results obtained. In cases in which it is not expected to perform sample processing within the first 24h following a bone marrow puncture, a stabilising solution such as TransFix should be used to avoid deterioration of cells.


Standardization of Flow Cytometric Minimal Residual Disease Evaluation in Acute Lymphoblastic Leukemia: Multicentric Assessment Is Feasible

Sample Type: Bone Marrow (BCP- and T-ALLs)

Analysis Method: Flow Cytometry


Dworzak, M. N., Gaipa, G., Ratei, R., Veltroni, M., Schumich, A., Maglia, O., Karawajew, L., Benetello, A., Pötschger, U., Husak, Z., Gadner, H., Biondi, A., Ludwig, W.-D. and Basso, G.


Cytometry B Clin Cytom. 2008 Nov;74(6):331-40.

Flow cytometric (FCM) assessment of minimal residual disease (MRD) in acute lymphoblastic leukaemia (ALL) patients was assessed at 3 different sites in Italy and one in Germany to see whether standardization was possible.MRD-evaluation by FCM in ALL can be standardized for reliable multicentric assessment in large trials.In order to assess the inter-laboratory concordance, artificial samples were created using TransFix. TransFix was used to stabilise leukemic cells from nine patients (seven B cell ALL and two T cell ALL) and these cells were mixed into bone marrow preparations at different concentrations. These were then sent to the sites for FCM analysis. The concordance between all four centres was 98%. Therefore, TransFix was shown to be successful in stabilising leukemic cells.

Call for Papers : Publication Rewards

If your research using Cytomark's reagents culminates in a publication, could you share your accomplishment with us?

We are offering a Free Amazon Kindle for each New Publication.

It's easy: just send us your peer-reviewed journal article published within the last 2 years. The article should reference at least one Cytomark product, and should state the Product Code. As long as the publication doesn’t already exist in our bibliography, we will be delighted to reward you with a Kindle.

Please send your articles to

One Kindle per journal article.

back to top